Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - protac
5
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers
SHORT DESCRIPTION Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Yanis Boumber * Principal Investigator NU Tech ID: NU 2023-140 IP STATUS U.S....
Published: 6/16/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Cancer/Oncology
,
Head and neck cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (
PROTAC
) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 6/16/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
BIO2026
,
Bladder cancer
,
Breast cancer
,
Cancer/Oncology
,
Covalent inhibitor
,
Lymphoma
,
Melanoma
,
PreSeed/Seed
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081 INVENTORS Sarki Abdulkadir (PI)* Northwestern University Feinberg School of Medicine, Department of Urology Gary Schiltz (PI)* Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION A small molecule
PROTAC
technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 6/16/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
BIO2026
,
Cancer/Oncology
,
Leukemia
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Compounds and methods for FBXW7-R465C-mediated protein degradation
NU 2024-224 INVENTORS Xiaoyu Zhang* Ananya Basu SHORT DESCRIPTION This invention describes novel heterobifunctional compounds that exploit a somatic mutant of the FBXW7 E3 ligase for targeted protein degradation. BACKGROUND Targeted protein degradation (TPD) is a powerful therapeutic strategy that harnesses the cell's natural machinery...
Published: 6/17/2026
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIO2026
,
Cancer/Oncology
,
PROTAC
,
Targeted therapy
,
Therapeutics
,
TPD - Targeted protein degradation
Category(s):
Life Sciences > Therapeutics
IDO-
PROTAC
s for Improving the Anti-Cancer Immune Response
NU 2020-137 INVENTORS Derek Wainwright* Gary Schiltz SHORT DESCRIPTION IDO-
PROTAC
that target immunosuppressive IDO activity via degradation ABSTRACT The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 6/16/2026
|
Updated: 5/27/2022
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
BIO2026
,
Brain cancer
,
Cancer/Oncology
,
Colon cancer
,
Endometrial cancer
,
Immunotherapy
,
Pancreatic cancer
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics